Singapore markets open in 30 minutes

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
277.37+3.43 (+1.25%)
At close: 04:00PM EDT
277.00 -0.37 (-0.13%)
After hours: 07:54PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close273.94
Open273.55
Bid263.87 x 100
Ask277.44 x 200
Day's range273.38 - 279.78
52-week range211.71 - 329.72
Volume2,278,372
Avg. volume2,926,600
Market cap148.775B
Beta (5Y monthly)0.60
PE ratio (TTM)22.19
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield9.00 (3.28%)
Ex-dividend date16 May 2024
1y target estN/A
  • Reuters

    Amgen investors await weight-loss drug data

    (Reuters) -Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug candidates when it reports quarterly earnings on Thursday. Amgen has said it expects to have first-in-human results from a small, early-stage trial of experimental oral compound AMG786 before the end of June. "We are still collecting and analyzing the data," Amgen Chief Scientific Officer Jay Bradner told Reuters in an interview.

  • Benzinga

    Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab

    Generic and biosimilar manufacturer Sandoz AG (OTC:SDZNY) (OTC:SDZXF) reached an agreement on Tuesday with Amgen Inc (NASDAQ:AMGN) to resolve all patent litigation related to its U.S. denosumab biosimilars. Sandoz said in a statement that the agreement clears the way for the launch of denosumab biosimilars Jubbonti and Wyost on May 31, 2025, or earlier under certain circumstances. “The terms of the agreement will not impact our previously disclosed 2024 guidance,” Sandoz said. Sandoz received FD

  • Zacks

    Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?

    Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.